Opthea (OPT) Price & Analysis

Compare

42 Followers

OPT Stock Chart & Stats

AU$0.60

-AU$0.04(-5.10%)

At close: Jan 09 4:00 PM EST

AU$0.60

-AU$0.04(-5.10%)

Day’s Range― - ―

52-Week RangeAU$0.59 - AU$1.05

Previous CloseN/A

Volume897.04K

Average Volume (3M)0.00

Market Cap

AU$738.77M

Enterprise ValueAU$777.55M

Total Cash (Recent Filing)AU$48.22M

Total Debt (Recent Filing)AU$245.88M

Price to Earnings (P/E)―

Beta4.44

Next Earnings

Feb 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding1,367,978,100

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)-3.65

Price to Sales (P/S)29392.74

P/FCF Ratio-4.63

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt EliminationEliminating debt reduces financial risk and interest obligations, enhancing financial flexibility and stability for future growth initiatives.

R&D Tax IncentiveThe R&D tax incentive boosts cash flow and supports ongoing research efforts, aiding in the development of innovative therapies and long-term growth.

Operational StreamliningStreamlining operations and reducing costs enhance financial health, allowing Opthea to allocate resources more effectively towards strategic initiatives.

Bears Say

Negative EquityNegative equity indicates accumulated losses, posing risks to financial stability and increasing reliance on external funding for operations.

Cash BurnPersistent cash burn necessitates ongoing external funding, which could lead to dilution and limit the company's ability to invest in growth.

Revenue VolatilityHighly volatile revenue reflects uncertainty in financial performance, complicating planning and potentially undermining investor confidence.

Opthea News

Opthea Streamlines Operations, Refocuses on LAM Program as ASX Reinstatement Sought

The latest update is out from Opthea ( ($AU:OPT) ). Opthea has reported a quarter marked by operational...

18d ago

Opthea Simplifies Capital Structure as 4.45 Million Options and Rights Lapse

Opthea ( ($AU:OPT) ) just unveiled an update. Opthea Limited has notified the Australian Securities Exchange that a...

1M ago

Opthea Grants 41 Million Options to Non-Executive Director Katherine Connell

Opthea ( ($AU:OPT) ) has provided an update. Opthea has disclosed a change in director Katherine Connell’s interests...

2M ago

Opthea Issues 82 Million Unquoted Options Under Employee Incentive Scheme

Opthea ( ($AU:OPT) ) has shared an update. Opthea Limited has issued 82 million unquoted options under an...

2M ago

Opthea to Host Corporate Update Webinar

Opthea ( ($AU:OPT) ) just unveiled an update. Opthea Limited announced it will provide a corporate update on...

2M ago

Opthea Limited Secures Shareholder Approval for Key Resolutions

Opthea ( ($AU:OPT) ) has shared an announcement. Opthea Limited announced the successful passage of all resolutions at...

3M ago

Opthea Streamlines Operations and Strengthens Financial Position

The latest announcement is out from Opthea ( ($AU:OPT) ). Opthea Limited has simplified its operations and resolved...

4M ago

Opthea to Delist from Nasdaq, Focuses on ASX and Australian Market

The latest announcement is out from Opthea ( ($AU:OPT) ). Opthea Limited has announced its decision to voluntarily...

4M ago

Opthea Announces Key Management Appointments

The latest update is out from Opthea ( ($AU:OPT) ). Opthea Limited has announced the appointment of Mr....

4M ago

Opthea Secures A$10.8 Million R&D Tax Incentive to Boost Innovation

The latest update is out from Opthea ( ($AU:OPT) ). Opthea Limited has announced the receipt of an...

4M ago

Opthea terminates COAST trial, announces ShORe trial misses endpoint

Opthea (OPT) announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline...

11M ago

OPT

Opthea downgraded to Perform from Outperform at Oppenheimer

Oppenheimer downgraded Opthea (OPT) to Perform from Outperform. Published first on TheFly – the ultimate source for real-time,...

11M ago

OPT

Opthea downgraded to Market Perform from Outperform at Leerink

Leerink analyst Marc Goodman downgraded Opthea (OPT) to Market Perform from Outperform. Published first on TheFly – the...

11M ago

OPT

Opthea cut to Market Perform at Leerink on failed sozinibercept trial

Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12....

11M ago

OPT

OPT FAQ

What was Opthea Limited’s price range in the past 12 months?

Opthea Limited lowest share price was AU$0.59 and its highest was AU$1.05 in the past 12 months.

What is Opthea Limited’s market cap?

Opthea Limited’s market cap is AU$738.77M.

When is Opthea Limited’s upcoming earnings report date?

Opthea Limited’s upcoming earnings report date is Feb 26, 2026 which is in 9 days.

How were Opthea Limited’s earnings last quarter?

Opthea Limited released its earnings results on Aug 29, 2025. The company reported -AU$0.04 earnings per share for the quarter, missing the consensus estimate of -AU$0.013 by -AU$0.027.

Is Opthea Limited overvalued?

According to Wall Street analysts Opthea Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Opthea Limited pay dividends?

Opthea Limited does not currently pay dividends.

What is Opthea Limited’s EPS estimate?

Opthea Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Opthea Limited have?

Opthea Limited has 1,367,978,100 shares outstanding.

What happened to Opthea Limited’s price movement after its last earnings report?

Opthea Limited reported an EPS of -AU$0.04 in its last earnings report, missing expectations of -AU$0.013. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Opthea Limited?

Currently, no hedge funds are holding shares in AU:OPT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Opthea Stock Smart Score

Neutral

Blogger Sentiment

Bullish

AU:OPT Sentiment 70%
Sector Average ―

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-69.91%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Opthea Limited

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.